Compare · BBNX vs WST
BBNX vs WST
Side-by-side comparison of Beta Bionics Inc. (BBNX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.75B, about 48.6x BBNX ($467.9M).
- Over the past year, BBNX is down 29.8% and WST is up 50.1% - WST leads by 79.9 points.
- WST has been more active in the news (17 items in the past 4 weeks vs 4 for BBNX).
- BBNX has more recent analyst coverage (16 ratings vs 15 for WST).
- Company
- Beta Bionics Inc.
- West Pharmaceutical Services Inc.
- Price
- $10.49-0.80%
- $321.96+2.67%
- Market cap
- $467.9M
- $22.75B
- 1M return
- +7.04%
- +21.08%
- 1Y return
- -29.79%
- +50.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 17
- Recent ratings
- 16
- 15
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest BBNX
- Beta Bionics to Present at the Bank of America Securities Health Care Conference
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- SEC Form DEFA14A filed by Beta Bionics Inc.
- SEC Form DEF 14A filed by Beta Bionics Inc.
- Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
- Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
Latest WST
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
- Director Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)
- Director Keller Deborah L was granted 791 shares, increasing direct ownership by 7% to 11,560 units (SEC Form 4)
- Director Joseph Molly was granted 791 shares, increasing direct ownership by 22% to 4,398 units (SEC Form 4)
- Director Haugen Janet Brutschea was granted 791 shares, increasing direct ownership by 50% to 2,373 units (SEC Form 4)
- Director Friel Robert F was granted 791 shares, increasing direct ownership by 17% to 5,513 units (SEC Form 4)
- Director Feehery William F was granted 791 shares, increasing direct ownership by 2% to 32,519 units (SEC Form 4)
- Director Buthman Mark A was granted 791 shares, increasing direct ownership by 2% to 44,309 units (SEC Form 4)